直接血抑制剂通过PI3K/p-AKT通路抑制1型糖尿病的发展
Ahmed G Alharbi1,2, Hussien M Ali1,3, Ahmed H Alhowail1
1Department of Pharmacology and Toxicology, College of Pharmacy, Qassim University, Buraydah 51452, Saudi Arabia.
Current molecular pharmacology
|May 20, 2025
概括
凝血级联激活与通过PI3K/AKT通路的1型糖尿病发展有关. 像达比加特兰这样的直接血栓激素抑制剂在高危人群中显示出预防1型糖尿病的潜力.
科学领域:
- 免疫学 免疫学 免疫学
- 血液学 血液学 血液学
- 内分泌学 在内分泌学.
背景情况:
- 1型糖尿病 (T1DM) 是一种自身免疫性疾病,其特征是胰岛素缺乏和高血糖.
- 凝血级联激活和T1DM发展之间的关系尚未得到充分证实.
研究的目的:
- 研究凝血系统在T1DM进展中的作用.
- 评估达比加特兰的保护作用,一种直接的血栓激素抑制剂,在小鼠模型中评估链毒素 (STZ) 诱导的T1DM.
主要方法:
- 小鼠被分为四组:对照组,达比加特兰治疗组,STZ治疗组和STZ+达比加特兰组.
- 评估的参数包括血糖,血小板,血清胰岛素和胰腺组织病理学.
- 在胰腺组织中使用免疫光学研究蛋白质表达 (PI3K,p-Akt,胰岛素,纤维素素).
主要成果:
- 受STZ诱导的T1DM小鼠表现出纤维素,PI3K和p-Akt表达的增加,以及血小板狭窄.
- STZ治疗降低了胰腺胰岛素水平.
- 达比加特兰联合治疗使纤维素素,PI3K和p-Akt水平正常化,血小板数量增加,胰岛素表达恢复.
结论:
- 由PI3K/AKT通路调解的凝血级联激活,有助于T1DM.
- 直接抗血素治疗,如达比加特兰,可能为风险人群的T1DM预防提供一种新的策略.
相关概念视频
Dipeptidyl Peptidase 4 Inhibitors
146
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
146
Diabetes Mellitus: Overview and Type I Subtype
2.3K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.3K
Glucagon-like Receptor Agonists
277
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
277
Insulin: The Receptor and Signaling Pathways
1.1K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.1K
The JAK-STAT Signaling Pathway
8.6K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.6K
Diabetes Mellitus: Type 2 and Gestational
2.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.1K


